Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CERE | Common Stock | Options Exercise | +160K | 160K | Dec 19, 2023 | Direct | F1, F2 | |||
holding | CERE | Common Stock | 83.9K | Dec 19, 2023 | By Trust | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CERE | Restricted Stock Units | Options Exercise | $0 | -160K | -100% | $0.00* | 0 | Dec 19, 2023 | Common Stock | 160K | Direct | F1, F2 |
Id | Content |
---|---|
F1 | In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. |
F2 | Each RSU represented the contingent right to receive one share of the Issuer's common stock. |
F3 | Shares held by The Ronald C Renaud Jr Trust 2 U/A DTD 06/08/2007, of which the Reporting Person and his spouse serve as trustees. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |